A meta-analysis of seven clinical trials reported prolonged PFS in patients with advanced-stage EGFRm-positive NSCLC treated with 1st generation EGFR-TKIs versus chemotherapy, with the greatest benefit observed in patients with exon 19 mutations (8). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.